• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

January 31, 2017

Trending News Today: Patients File Lawsuit Over Insulin Cost Spike

Author(s):

Lauren Santye, Assistant Editor

Top news of the day from across the health care landscape.

Lung cancer screenings may take more effort than the results merit, as only a small number of individuals with cancer are identified through this procedure, according to NPR. In a study conducted by the Veterans Health Administration, which included 4246 patients who were eligible for screening, investigators sought to examine the overall benefits and potential harms of setting up a screening program in a large medical institution. In general, screenings can identify cancers, but a vast majority of test results produce false alarms, NPR reported. Although the low-dose CT scans were offered at no cost, approximately half of the participants declined to take the test. The results of the study showed that 55% of patients had lung nodules—–often leading to follow-up appointments and further scans––but very few of the nodules are actually a cause for concern, NPR reported. Overall, 31 cases of lung cancer were identified, of which approximately 20 were in the early and most treatable stage. Although the 20 or so patients who had their cancer detectable saw benefits from the screening, “but that has to be weighed against the amount of effort on the part of both patients and staff, and the anxiety, the worry, that a false alarm will cause among patients,” lead investigator Dr Linda Kinsinger told NPR.

A generic drug used to treat pinworms is being investigated as a potential cancer drug, according to NPR. Mebendazole has been used for more than 40 years to treat parasitic infections, and in prior mice studies, the drug was found to stave off cancer development. Currently, two phase 1 studies are examining the safety of mebendazole in children and adults with brain cancer. According to the investigators, the drug appears to be safe and well-tolerated by patients thus far. The next step will be to look for a benefit in a phase 2 trial of individuals with cancer. According to Bruce Bloom, president and chief science officer of Cures Within Reach, which helped fund the studies, it’s unlikely that mebendazole, or any other single repurposed drug, will cure cancer; however, they may be able to help the body manage cancer.

Eleven patients have filed a lawsuit against 3 drug companies for systematically increasing the cost of insulin in an alleged fraudulent-pricing scheme that buried patients with astronomical out-of-pocket costs, The Washington Post reported. Humalog, a version of insulin launched 2 decades ago at a list price of $21 a vial, has increased to $255 a vial. The lawsuit, filed in the US District Court in Massachusetts, claims that drug companies have steadily increased the sticker price of insulin in order to expand their discounts, but have not lowered the overall cost. The lawsuit alleges that it violates the Racketeer Influenced and Corrupt Organizations Act, as well as state consumer protection laws, the Post reported.

Related Videos
Pharmacist and patient in a retail/community pharmacy setting -- Image credit: Zamrznuti tonovi | stock.adobe.com
Menoapuse spelled with wooden blocks -- Image credit: loran4a | stock.adobe.com
Related Content
Advertisement
Trastuzumab, pertuzumab binding to breast cancer cells | Image Credit: © LASZLO - stock.adobe.com
May 16th 2025

Adding Pertuzumab to Trastuzumab and Chemotherapy Reduced Risk of Death by 17% in HER2+ Breast Cancer

Alexandra Gerlach, Associate Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
3d rendered medically accurate illustration of a bladder tumor
May 16th 2025

Durvalumab Regimen Improves Disease-Free Survival in High-Risk Non-Muscle-Invasive Bladder Cancer

Luke Halpern, Assistant Editor
Pharmacy Times pharmacy focus oncology edition
May 5th 2025

Novel HER2-low Therapies and Pharmacist-Led ADC Sequencing

Alexandra Gerlach, Associate Editor
FDA approval seal -- Image credit: Aquir | stock.adobe.com
May 15th 2025

Retifanlimab-Dlwr Becomes First and Only FDA-Approved First-Line Treatment for Advanced Anal Cancer

Gillian McGovern, Associate Editor
Olaparib box | Image Credit: © luchschenF - stock.adobe.com
May 15th 2025

Gap-Scheduled Olaparib Plus Neoadjuvant Chemotherapy Improved Survival in Patients With gBRCAm TBNC

Alexandra Gerlach, Associate Editor
Related Content
Advertisement
Trastuzumab, pertuzumab binding to breast cancer cells | Image Credit: © LASZLO - stock.adobe.com
May 16th 2025

Adding Pertuzumab to Trastuzumab and Chemotherapy Reduced Risk of Death by 17% in HER2+ Breast Cancer

Alexandra Gerlach, Associate Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
3d rendered medically accurate illustration of a bladder tumor
May 16th 2025

Durvalumab Regimen Improves Disease-Free Survival in High-Risk Non-Muscle-Invasive Bladder Cancer

Luke Halpern, Assistant Editor
Pharmacy Times pharmacy focus oncology edition
May 5th 2025

Novel HER2-low Therapies and Pharmacist-Led ADC Sequencing

Alexandra Gerlach, Associate Editor
FDA approval seal -- Image credit: Aquir | stock.adobe.com
May 15th 2025

Retifanlimab-Dlwr Becomes First and Only FDA-Approved First-Line Treatment for Advanced Anal Cancer

Gillian McGovern, Associate Editor
Olaparib box | Image Credit: © luchschenF - stock.adobe.com
May 15th 2025

Gap-Scheduled Olaparib Plus Neoadjuvant Chemotherapy Improved Survival in Patients With gBRCAm TBNC

Alexandra Gerlach, Associate Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.